Loading…
Single oral dose pharmacokinetics of the two main components of pristinamycin in humans
A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and...
Saved in:
Published in: | Journal of antimicrobial chemotherapy 1990-04, Vol.25 (4), p.651-656 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253 |
---|---|
cites | |
container_end_page | 656 |
container_issue | 4 |
container_start_page | 651 |
container_title | Journal of antimicrobial chemotherapy |
container_volume | 25 |
creator | Koechlin, Christophe Kempf, Jean-François Jehl, François Monteil, Henri |
description | A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods. |
doi_str_mv | 10.1093/jac/25.4.651 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79818848</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79818848</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS0EKtOBHVukbGDVTK-fsZfQForUgsRDIDbWjeMwaRN7amcE_fe4zKhdYlny4js60vlMyAsKKwqGH1-hO2ZyJVZK0kdkQYWCmoGhj8kCOMi6EZI_JYc5XwGAkkofkANGKZMCFuT7lyH8Gn0VE45VF7OvNmtME7p4PQQ_Dy5Xsa_mta_m37GacAiVi9MmBh_mf2iThjwPAadbV1i56-2EIT8jT3ocs3--f5fk27uzryfn9cWn9x9O3lzUjgPMtXDQUGaYRtd3ihkhUOm-A2NUrx1ruVaOCt9K12ra-g4k7zqkUjCveJnAl-T1rneT4s3W59lOQ3Z-HDH4uM22MZpqLfR_g1Q2XPFyluRoF3Qp5px8b8vECdOtpWDvhNsi3DJphS3CS_zlvnfbTr67D-8NF_5qzzE7HPuEwQ35odOI8iv6bki9yxWd_s89x3RtVcMbac9__LSXpx_fgjml9jP_C-1Kl8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15736333</pqid></control><display><type>article</type><title>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</title><source>Oxford University Press Archive</source><creator>Koechlin, Christophe ; Kempf, Jean-François ; Jehl, François ; Monteil, Henri</creator><creatorcontrib>Koechlin, Christophe ; Kempf, Jean-François ; Jehl, François ; Monteil, Henri</creatorcontrib><description>A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/25.4.651</identifier><identifier>PMID: 2112540</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Chromatography, High Pressure Liquid ; Female ; Half-Life ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Virginiamycin - administration & dosage ; Virginiamycin - blood ; Virginiamycin - pharmacokinetics</subject><ispartof>Journal of antimicrobial chemotherapy, 1990-04, Vol.25 (4), p.651-656</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19400085$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2112540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koechlin, Christophe</creatorcontrib><creatorcontrib>Kempf, Jean-François</creatorcontrib><creatorcontrib>Jehl, François</creatorcontrib><creatorcontrib>Monteil, Henri</creatorcontrib><title>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Female</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Virginiamycin - administration & dosage</subject><subject>Virginiamycin - blood</subject><subject>Virginiamycin - pharmacokinetics</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><recordid>eNqFkUtv1DAUhS0EKtOBHVukbGDVTK-fsZfQForUgsRDIDbWjeMwaRN7amcE_fe4zKhdYlny4js60vlMyAsKKwqGH1-hO2ZyJVZK0kdkQYWCmoGhj8kCOMi6EZI_JYc5XwGAkkofkANGKZMCFuT7lyH8Gn0VE45VF7OvNmtME7p4PQQ_Dy5Xsa_mta_m37GacAiVi9MmBh_mf2iThjwPAadbV1i56-2EIT8jT3ocs3--f5fk27uzryfn9cWn9x9O3lzUjgPMtXDQUGaYRtd3ihkhUOm-A2NUrx1ruVaOCt9K12ra-g4k7zqkUjCveJnAl-T1rneT4s3W59lOQ3Z-HDH4uM22MZpqLfR_g1Q2XPFyluRoF3Qp5px8b8vECdOtpWDvhNsi3DJphS3CS_zlvnfbTr67D-8NF_5qzzE7HPuEwQ35odOI8iv6bki9yxWd_s89x3RtVcMbac9__LSXpx_fgjml9jP_C-1Kl8w</recordid><startdate>199004</startdate><enddate>199004</enddate><creator>Koechlin, Christophe</creator><creator>Kempf, Jean-François</creator><creator>Jehl, François</creator><creator>Monteil, Henri</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>199004</creationdate><title>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</title><author>Koechlin, Christophe ; Kempf, Jean-François ; Jehl, François ; Monteil, Henri</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Female</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Virginiamycin - administration & dosage</topic><topic>Virginiamycin - blood</topic><topic>Virginiamycin - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koechlin, Christophe</creatorcontrib><creatorcontrib>Kempf, Jean-François</creatorcontrib><creatorcontrib>Jehl, François</creatorcontrib><creatorcontrib>Monteil, Henri</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koechlin, Christophe</au><au>Kempf, Jean-François</au><au>Jehl, François</au><au>Monteil, Henri</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single oral dose pharmacokinetics of the two main components of pristinamycin in humans</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1990-04</date><risdate>1990</risdate><volume>25</volume><issue>4</issue><spage>651</spage><epage>656</epage><pages>651-656</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>A preliminary study of the pharmacokinetics of the two main components of pristinamycin, PIA and PIIA is reported. A single oral dose of 2 g of pristinamycin was administered to six patients with normal renal and hepatic function. The samples were withdrawn during 9·5 h and assayed by HPLC. PIA and PIIA plasma levels evolved in parallel in each subject and their kinetic parameters were comparable: Tmax of 3·25± 1·80 h and 3·08± 1·98 h, Cmax of 0·760±0·427 mg/l and 0·581±0·285mg/l, elimination half-life of 4·03±2·77 h−1 and 2·83±0·75 h−1 respectively. The relative proportions of PIA and PIIA, which govern the antibacterial activity of the mixture, were maintained during the study in the range of values leading to 90–100% of optimal activity against Staphylococcus aureus. The sum of the plasma concentrations of PIA and PIIA, which can be considered to be equivalent to the concentration of total pristinamycin, was superior to the MICs for the most susceptible staphylococal strains during the entire period of study. On the other hand, the sum of PIA and PIIA concentrations exceeded the MICs for the less susceptible strains for only 4 h. These results differ from the scanty pharmacokinetic data presently available, which were obtained by microbiological methods.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>2112540</pmid><doi>10.1093/jac/25.4.651</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7453 |
ispartof | Journal of antimicrobial chemotherapy, 1990-04, Vol.25 (4), p.651-656 |
issn | 0305-7453 1460-2091 |
language | eng |
recordid | cdi_proquest_miscellaneous_79818848 |
source | Oxford University Press Archive |
subjects | Administration, Oral Adult Aged Aged, 80 and over Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Chromatography, High Pressure Liquid Female Half-Life Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Virginiamycin - administration & dosage Virginiamycin - blood Virginiamycin - pharmacokinetics |
title | Single oral dose pharmacokinetics of the two main components of pristinamycin in humans |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A10%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single%20oral%20dose%20pharmacokinetics%20of%20the%20two%20main%20components%20of%20pristinamycin%20in%20humans&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Koechlin,%20Christophe&rft.date=1990-04&rft.volume=25&rft.issue=4&rft.spage=651&rft.epage=656&rft.pages=651-656&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/25.4.651&rft_dat=%3Cproquest_cross%3E79818848%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-4c0712928acfd62944a68fd0996f8c2b386c14eb5cb81bed053dda1542e631253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15736333&rft_id=info:pmid/2112540&rfr_iscdi=true |